On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a fruitful discussion with patient advocates from the AMRO region about the pandemic’s situation reports and challenges related to individuals with thalassaemia in these areas.
IMR-687 Receives FDA Fast Track & Rare Pediatric Disease Designations for the Treatment of β-Τhalassaemia
August 5, 2020
Dezember 30, 2020
3 Wochen vor
Überprüfen Sie auchSchließen